Aberdeen Group plc grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 483.6% during the 3rd quarter, Holdings Channel reports. The firm owned 792,576 shares of the medical research company’s stock after purchasing an additional 656,777 shares during the period. Aberdeen Group plc’s holdings in Charles River Laboratories International were worth $233,818,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. Allworth Financial LP lifted its stake in Charles River Laboratories International by 2,931.8% in the third quarter. Allworth Financial LP now owns 10,096 shares of the medical research company’s stock valued at $2,978,000 after buying an additional 9,763 shares in the last quarter. Fisher Asset Management LLC lifted its position in Charles River Laboratories International by 1,334.7% in the 3rd quarter. Fisher Asset Management LLC now owns 14,376 shares of the medical research company’s stock valued at $4,241,000 after acquiring an additional 13,374 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Charles River Laboratories International by 457.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 436,055 shares of the medical research company’s stock worth $128,641,000 after purchasing an additional 357,817 shares in the last quarter. Eurizon Capital SGR S.p.A. increased its holdings in Charles River Laboratories International by 6,849.6% during the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 35,860 shares of the medical research company’s stock worth $10,579,000 after purchasing an additional 35,344 shares in the last quarter. Finally, Fifth Third Bancorp raised its stake in shares of Charles River Laboratories International by 24.1% in the 3rd quarter. Fifth Third Bancorp now owns 22,112 shares of the medical research company’s stock valued at $6,523,000 after purchasing an additional 4,299 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.
Insider Buying and Selling at Charles River Laboratories International
In other news, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the transaction, the director directly owned 1,438 shares in the company, valued at approximately $410,175.12. The trade was a 28.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Shannon M. Parisotto sold 2,156 shares of the business’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the transaction, the executive vice president directly owned 4,807 shares in the company, valued at $1,655,578.87. The trade was a 30.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,352 shares of company stock worth $20,291,281 over the last 90 days. Company insiders own 1.30% of the company’s stock.
Wall Street Analyst Weigh In
CRL has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Charles River Laboratories International in a research report on Monday, September 28th. Wall Street Zen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Evercore set a $330.00 target price on Charles River Laboratories International in a research report on Friday, September 25th. Morgan Stanley boosted their target price on Charles River Laboratories International from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Finally, Argus set a $330.00 price target on Charles River Laboratories International in a research report on Thursday, September 17th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $311.67.
Charles River Laboratories International Trading Down 0.7%
Shares of Charles River Laboratories International stock opened at $338.27 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $146.20 and a 12-month high of $379.63. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76. The business’s 50 day moving average is $311.21 and its 200-day moving average is $228.24. The stock has a market cap of $16.21 billion, a P/E ratio of 371.73, a P/E/G ratio of 3.08 and a beta of 1.36.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million for the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.43 earnings per share. Equities research analysts predict that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.
Charles River Laboratories International Company Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Further Reading
- Five stocks we like better than Charles River Laboratories International
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
